NR4A1 and breast carcinoma: Table 1 shows that 48.8% of women interrupted treatment because of adverse effects (older age was correlated with more interruptions due to adverse effects), 40.0% had no clear reason, 29.4% had other reasons related to breast cancer (advanced stage, progression, negative hormone receptors, treatment changes), 14.7% had other clinical reasons, and 6.5% were lost to follow-up for different reasons (transfer to other Spanish autonomous communities or to a private hospital).